Theravance Biopharma, Inc. $TBPH Position Decreased by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 62.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,477 shares of the biopharmaceutical company’s stock after selling 30,440 shares during the period. Hsbc Holdings PLC’s holdings in Theravance Biopharma were worth $354,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in TBPH. Quarry LP acquired a new stake in Theravance Biopharma during the third quarter valued at approximately $26,000. Mirae Asset Global Investments Co. Ltd. grew its position in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 515 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares in the last quarter. CIBC Private Wealth Group LLC increased its holdings in shares of Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 781 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TBPH shares. JonesTrading lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. TD Cowen upped their target price on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a report on Monday, March 23rd. HC Wainwright lowered Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price target for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Finally, Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Eight research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $19.40.

Theravance Biopharma Stock Performance

TBPH stock opened at $16.93 on Friday. The firm has a 50 day simple moving average of $16.62 and a 200 day simple moving average of $17.17. Theravance Biopharma, Inc. has a 52 week low of $10.82 and a 52 week high of $21.03. The stock has a market cap of $872.79 million, a P/E ratio of 7.70 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The company had revenue of $17.70 million during the quarter. Sell-side analysts predict that Theravance Biopharma, Inc. will post 1.54 EPS for the current year.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the transaction, the senior vice president directly owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 273,871 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $17.23, for a total value of $4,718,797.33. Following the sale, the insider owned 9,237,279 shares of the company’s stock, valued at approximately $159,158,317.17. This represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 350,011 shares of company stock worth $6,008,309. 7.65% of the stock is currently owned by corporate insiders.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.